Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Who May Qualify: - Participants with clinical tumour stage T2-T4aN0/1M0 or T1N1M0 with transitional or mixed transitional cell histology - Patients must be planning to undergo radical cystectomy - Patients who have not received prior systemic chemotherapy or immunotherapy for treatment of muscle-invasive bladder cancer - You should be able to carry out daily activities with 0 level of ability (ECOG 0) or 1 - Minimum life expectancy of 12 weeks at first dose of study medication Who Should NOT Join This Trial: - Evidence of lymph node (N2-N3) or metastatic (M1) disease - Inoperable tumour(s) with fixation to the pelvic wall on clinical examination - Prior exposure to immune-mediated therapy including, but not limited to, other anti CTLA-4, anti-PD 1, anti-PD L1 and anti-PD-L2 antibodies, excluding Bacillus Calmette-Guérin - Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab - Any concomitant medication known to be contraindicated to the chemotherapy (ddMVAC or gem/cis). - Uncontrolled intercurrent illness. Always talk to your doctor about whether this trial is right for you.